{"disease":{"id":"castrate-resistant-prostate-cancer","name":"castrate resistant prostate cancer"},"drugs":{"marketed":[{"drug_id":"sipuleucel-t","indication_name":"Metastatic castrate-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SIPULEUCEL-T","company_name":"","drug_phase":"marketed","molecular_target":"PAP","drug_class":"Autologous Cellular Immunotherapy [EPC]","quality_score":10,"revenue":null,"mechanism":"PROVENGE induces an immune response against PAP, an antigen found in most prostate cancers."},{"drug_id":"sipuleucel-t","indication_name":"Metastatic castrate-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SIPULEUCEL-T","company_name":"","drug_phase":"marketed","molecular_target":"PAP","drug_class":"Autologous Cellular Immunotherapy [EPC]","quality_score":10,"revenue":null,"mechanism":"PROVENGE induces an immune response against PAP, an antigen found in most prostate cancers."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06783127","title":"Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Santa Chiara Hospital","has_results":false},{"nct_id":"NCT04597125","title":"RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":654,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06551324","title":"A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT00838201","title":"Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":384,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT06702995","title":"Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":307,"lead_sponsor_name":"Evopoint Biosciences Inc.","has_results":false},{"nct_id":"NCT03314324","title":"A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":250,"lead_sponsor_name":"Gustave Roussy, Cancer Campus, Grand Paris","has_results":false},{"nct_id":"NCT02008058","title":"Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":213,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT07206056","title":"An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":188,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT01884285","title":"AZD8186 First Time In Patient Ascending Dose Study","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":147,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03729596","title":"MGC018 With or Without MGA012 in Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":143,"lead_sponsor_name":"MacroGenics","has_results":true},{"nct_id":"NCT04995614","title":"Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic CRPC Patients Treated With Radium-223","phase":"","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT05627752","title":"Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Zhongnan Hospital","has_results":false},{"nct_id":"NCT04038502","title":"Carboplatin or Olaparib for BRcA Deficient Prostate Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT06720532","title":"Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-Trial","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Hannah Schaefer","has_results":false},{"nct_id":"NCT05655715","title":"Checkpoint Inhibitors and SBRT for MCRPC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Herlev and Gentofte Hospital","has_results":false},{"nct_id":"NCT04969315","title":"TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Portage Biotech","has_results":false},{"nct_id":"NCT05415098","title":"Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":90,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT05252390","title":"NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":82,"lead_sponsor_name":"Nuvation Bio Inc.","has_results":false},{"nct_id":"NCT07214961","title":"Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80,"lead_sponsor_name":"ARTBIO Inc.","has_results":false},{"nct_id":"NCT04541225","title":"Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":74,"lead_sponsor_name":"Nuvation Bio Inc.","has_results":false},{"nct_id":"NCT02987829","title":"Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Tracon Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT03899467","title":"The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Suzhou Kintor Pharmaceutical Inc,","has_results":true},{"nct_id":"NCT05570994","title":"177Lu-HTK03170 in mCRPC With PSMA Positive Disease","phase":"PHASE1, PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":50,"lead_sponsor_name":"British Columbia Cancer Agency","has_results":false},{"nct_id":"NCT05766371","title":"Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT02259114","title":"A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT02814669","title":"Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT03737370","title":"Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Tufts Medical Center","has_results":false},{"nct_id":"NCT02826772","title":"Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Suzhou Kintor Pharmaceutical Inc,","has_results":false},{"nct_id":"NCT02607228","title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT04495179","title":"A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT06046040","title":"TmPSMA-02 in mCRPC","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT05159518","title":"A Study of PRT2527 in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Prelude Therapeutics","has_results":false},{"nct_id":"NCT01090765","title":"A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07090369","title":"Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Peter MacCallum Cancer Centre, Australia","has_results":false},{"nct_id":"NCT01818986","title":"Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":true},{"nct_id":"NCT03690141","title":"An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":16,"lead_sponsor_name":"Effector Therapeutics","has_results":true},{"nct_id":"NCT04053062","title":"LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":12,"lead_sponsor_name":"Bioray Laboratories","has_results":false},{"nct_id":"NCT01717898","title":"A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Charles Ryan","has_results":true},{"nct_id":"NCT04737109","title":"Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"David VanderWeele","has_results":true},{"nct_id":"NCT04768608","title":"PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT03041285","title":"Idronoxil Suppository Combine With Radiotherapy for Metastatic Prostate Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Royal North Shore Hospital","has_results":false},{"nct_id":"NCT06527690","title":"Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Latin American Cooperative Oncology Group","has_results":false},{"nct_id":"NCT05582031","title":"Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Translational Research in Oncology","has_results":false},{"nct_id":"NCT03386071","title":"Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false}],"total":44},"guidelines":[],"source":"Drug Landscape verified database"}